Human Mycoplasma IgG ELISA Kit (DEIA1720)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Size
96T
Sample
serum
Species Reactivity
Human
Intended Use
The Mycoplasma IgG ELISA test system provides a means for the qualitative detection of IgG antibodies to Mycoplasma pneumoniae in human sera. The test may aid in the determination of the patient"s serological status, or may aid in the diagnosis of disease associated with Mycoplasma pneumoniae.
Contents of Kit
1. Plate: 1 x 96 wells
2. Conjugate: 1 x 15 mL
3. Positive Control: 1 x 0.35 mL
4. Calibrator: 1 x 0.5 mL
5. Negative Control: 1 x 0.35 mL
6. Sample Diluent: 1 x 30 mL
7. TMB: 1 x 15 mL
8. Stop Solution: 1 x 15 mL
9. Wash buffer concentrate (10x): 1 x 100 mL
Storage
Store components of the kit at 2-8°C or -20°C upon arrival up to the expiration date. For more detailed information, please download the following document on our website.

Citations


Have you cited DEIA1720 in a publication? Let us know and earn a reward for your research.

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Mycoplasma hyopneumoniae Inhibits Porcine Beta-Defensin 2 Production by Blocking the Unfolded Protein Response To Facilitate Epithelial Adhesion and Infection

INFECTION AND IMMUNITY

Authors: Pan, Qiao; Wang, Xiumei; Liu, Tong; Yu, Ying; Li, Lu; Zhou, Rui; Li, Ganwu; Xin, Jiuqing

Mycoplasma hyopneumoniae causes the disease porcine enzootic pneumonia, a highly contagious and chronic disease affecting pigs. Understanding the molecular mechanisms of its pathogenicity is critical for developing effective interventions to control this swine respiratory disease. Here, we describe a novel virulence mechanism by which M. hyopneumoniae interferes with the host unfolded protein response (UPR) and eventually facilitates bacterial adhesion and infection. We observed that M. hyopneumoniae infection suppressed the UPR target molecules GRP78 and CHOP by reducing PKR-like endoplasmic reticulum kinase/eukaryotic initiation factor 2 alpha (PERK/eIF2 alpha) phosphorylation, ATF6 cleavage, and X-box binding protein 1 (XBP1) splicing. Interestingly, further analyses revealed that host UPR inhibition subsequently suppressed the NF-kappa B pathway, leading to the reduced production of porcine beta-defensin 2 (PBD-2), thus facilitating M. hyopneumoniae adherence and infection. This study provides new insights into the molecular pathogenesis of M. hyopneumoniae and sheds light upon its interactions with the host.

Clinical response to 2 protocols of aerosolized gentamicin in 46 dogs withBordetella bronchisepticainfection (2012-2018)

JOURNAL OF VETERINARY INTERNAL MEDICINE

Authors: Canonne, Aude Morgane; Roels, Elodie; Menard, Maud; Desquilbet, Loic; Billen, Frederic; Clercx, Cecile

Background Bordetella bronchiseptica(Bb) infection commonly causes respiratory disease in dogs. Gentamicin delivered by aerosol maximizes local drug delivery without systemic absorption but clinical response to protocols remains undetermined. Objectives To compare the clinical response to 2 protocols of aerosolized delivery of gentamicin in bordetellosis. Animals Forty-six dogs withBbinfection confirmed by culture or quantitative polymerase chain reaction on bronchoalveolar lavage. Methods Retrospective study. Administration of aerosolized gentamicin for >= 10 minutes q12h for >= 3 weeks using 4 mg/kg diluted with saline (group 1) or undiluted 5% solution (group 2). Clinical response firstly assessed after 3-4 weeks and treatment pursued by 3-weeks increments if cure not reached. Cure defined as absence of cough persisting at least a week after treatment interruption. Results Demographic data were similar between both groups. Clinical cure at 3-4 weeks was more frequently observed with the use of undiluted solution (19/33 vs 3/13 dogs,P= .03) in association with a shorter median duration of treatment (4 vs 6 weeks,P= .01). Dogs from group 2 having less than 1000 cells/mu L in lavage were also more likely to be cured at 3-4 weeks than dogs with more than 1000 cells/mu L [9/9 vs 10/19,P= .006] and median duration of treatment in that subgroup of animals was reduced (3 vs 5 weeks,P= .02). Conclusion and Clinical Importance Aerosolized delivery of gentamicin seems effective for inducing clinical cure inBbinfection. Clinical response appears better using undiluted 5% solution, particularly in the subgroup of dogs having less than 1000 cells/mu L in lavage.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket